Dose adjustments and adherence to adjuvant abemaciclib in a brazilian real-world scenario
Introduction: Abemaciclib combined with endocrine therapy is an established adjuvant treatment for high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. However, its prolonged use (up to two years) poses challenges related to tolerability and adherence,...